NasdaqCM - Nasdaq Real Time Price USD

Singular Genomics Systems, Inc. (OMIC)

Compare
21.90 0.00 (0.00%)
At close: November 21 at 4:00 PM EST
21.40 -0.48 (-2.19%)
After hours: November 21 at 4:00 PM EST
Loading Chart for OMIC
DELL
  • Previous Close 21.90
  • Open 21.35
  • Bid --
  • Ask --
  • Day's Range 21.03 - 21.90
  • 52 Week Range 5.34 - 23.41
  • Volume 6,958
  • Avg. Volume 107,400
  • Market Cap (intraday) 55.008M
  • Beta (5Y Monthly) 1.51
  • PE Ratio (TTM) --
  • EPS (TTM) -34.68
  • Earnings Date Nov 12, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 12.45

Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and spatial multiomics technology for researchers and clinicians to advance science and medicine. The company is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection with high-definition sequencing, gene fusion detection with ring-seq, and extended range sequencing; and PX instrument and associated consumables focusing on the single cell and spatial analysis markets. Singular Genomics Systems, Inc. was incorporated in 2016 and is based in San Diego, California.

www.singulargenomics.com

255

Full Time Employees

December 31

Fiscal Year Ends

Recent News: OMIC

View More

Performance Overview: OMIC

Trailing total returns as of 11/21/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

OMIC
58.70%
S&P 500
24.72%

1-Year Return

OMIC
80.25%
S&P 500
30.82%

3-Year Return

OMIC
94.69%
S&P 500
26.62%

5-Year Return

OMIC
97.48%
S&P 500
41.61%

Compare To: OMIC

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: OMIC

View More

Valuation Measures

Annual
As of 11/20/2024
  • Market Cap

    54.46M

  • Enterprise Value

    -8.89M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    20.18

  • Price/Book (mrq)

    0.44

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -24.27%

  • Return on Equity (ttm)

    -51.61%

  • Revenue (ttm)

    2.72M

  • Net Income Avi to Common (ttm)

    -91.89M

  • Diluted EPS (ttm)

    -34.68

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    133.39M

  • Total Debt/Equity (mrq)

    54.99%

  • Levered Free Cash Flow (ttm)

    -41.85M

Research Analysis: OMIC

View More

Company Insights: OMIC

Research Reports: OMIC

View More

People Also Watch